11P - Prognostic significance of different immunohistochemical markers in small cell lung cancer

Date 07 May 2017
Event ELCC 2017
Session Poster Display Session
Topics Small-Cell Lung Cancer
Thoracic malignancies
Pathology/Molecular Biology
Basic Scientific Principles
Presenter Eleni Gkika
Citation Annals of Oncology (2017) 28 (suppl_2): ii1-ii5. 10.1093/annonc/mdx090
Authors E. Gkika1, S. Beitinger2, S. Adebahr2, T. Schimek-Jasch2, S. Wiesemann3, C. Waller4, A. Grosu2, U. Nestle5, G. Kayser6
  • 1Department Of Radiation Oncology, University of Freiburg, 79106 - Freiburg/DE
  • 2Department Of Radiation Oncology, Medical Center – University of Freiburg, Freiburg/DE
  • 3Department Of Thorasic Surgery, Medical Center – University of Freiburg, Freiburg/DE
  • 4Department Of Internal Medicine-oncology, Mediacl Center - University of Freiburg, Freiburg/DE
  • 5Department Of Radiation Oncology, Freiburg University Medical Center, Freiburg/DE
  • 6Department Of Pathology, Mediacl Center - University of Freiburg, Freiburg/DE



To evaluate the role of different immunohistochemical markers concerning the overall and progression free survival in patients with small cell lung cancer (SCLC).


A total of 104 consecutive patients with histologically proven SCLC (limited and extensive disease) treated with chemotherapy and radiotherapy at the University Hospital of Freiburg, between 2005 and 2012 and available pathologic slices, were included in the analysis. The expression of different immunohistochemical markers from the tissue biopsy such as CD56, CD44, Chromogranin, Synaptophysin, TTF-1, GLUT-1, Hif-1 alpha, PD-1 und PD-L1 and MIB-1/KI-67 as well as the LDH und NSE from the initial blood sample were correlated with the overall survival (OS) and progression free survival (PFS) using the Kaplan Meier Method and Cox proportional hazards ratio. Furthermore, for CD44, Hif-1 alpha and GLUT-1 H-Scores were generated for further analysis.


Of the included 104 patients, 48 had limited disease (LD) and 53 extensive disease (ED) at diagnosis. The median overall survival calculated from diagnosis was 21 (95%CI 19-23) months for patients with LD and 13 (95%CI 11-15) months for patients with ED. Patients with higher LDH (HR: 1.003 95% CI 1.001-1.005, p < 0.001) and NSE (HR:1.004, 95%CI: 1.002-1.007, p < 0.001) at diagnosis had a worse OS. These factors correlated also with a worse PFS (HR: 1.002 95% CI 1.000-1.003 p = 0.011 and HR: 1.004, 95% 1.001-1.006, p = 0.002, respectively). Concerning the immunohistchemical markers only the expression of Synaptophysin correlated with a worse OS (HR 1.890, CI 95% 1.067-3.346, p = 0.029) but not with the PFS (HR: 1.761, 95% CI 0.963-3.222, p = 0.066). All other markers did not correlate with OS or PFS.


A positive immunhistochemical staining of synaptophysisn in patients with SCLC correlated with worse prognosis.

Clinical trial identification

Legal entity responsible for the study

University of Freiburg




All authors have declared no conflicts of interest.